Ripple is collaborating with Privy to integrate XRP Ledger (XRPL) support into Privy's developer platform. This partnership allows developers to create and manage XRPL wallets and handle transaction signing within their applications without building wallet infrastructure from scratch. The platform will support XRP, Ripple's RLUSD stablecoin, and other assets on the XRPL network. Privy, owned by Stripe, aims to enhance wallet functionality for developers building on XRPL.
The Ripple and Privy partnership on XRP Ledger wallets is the subject, with Pluang market data providing context. As of Oct 13, 2026 23:03 WIB, among 50 major cryptocurrencies on Pluang, 12 rose and 37 fell. Notable moves include EOS up 8.13% at Rp12.649 with a typical hold time of 87 days, ZIL down 7.68% at Rp61 with 82% sell order activity, and CRV down 6.28% at Rp6.074 with 91% buy order activity and a 62-day typical hold time.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
